KARS1 and parasitic infectious disease: Baragana et al. reported selective inhibitors of the apicomplexan LysRS, of which compound 5, when given at a low oral dosage (1.5 mg/kg once daily for 4 days), reduced parasitemia by over 90% in a malaria mouse model as it also inhibits C. parvum LysRS and growth of C. parvum parasites in vitro (Table 1) (52).